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Introduction {#sec001}
============

GBS is commonly isolated from the lower gastrointestinal tract or the female reproductive tract. Though normally an asymptomatic colonizer in these environments, this opportunistic pathogen can cause invasive disease, including pneumonia, sepsis, and meningitis \[[@pone.0226699.ref001]\]. The newborn is one of the primary populations at risk for the development of GBS invasive disease, with infection occurring through vertical transmission from the mother either by ascending bacterial infection *in utero* or during passage of the fetus through the colonized birth canal. Neonatal invasive disease is classified into two distinct categories: early-onset disease (EoD), or late-onset disease (LoD) \[[@pone.0226699.ref002], [@pone.0226699.ref003]\]. Early-onset infections typically occur in the first week of life, presenting acutely with pneumonia and respiratory failure complicated by bloodstream infection, septicemia, and sometimes meningitis. In contrast, GBS LoD occurs in infants up to 7 months of age, with more indolent symptom progression related to bacteremia and a high incidence (\~50%) of meningitis \[[@pone.0226699.ref004]\]. As a result of the high risk of infection in the neonate, implementation of late gestational screening and prescription of prophylactic antibiotics have become common practice in the US for expectant mothers during late stages of pregnancy or at delivery \[[@pone.0226699.ref005]\]. Colonized women are typically administered penicillin as a first-line drug, but in the case of allergy or suspected resistance, are instead treated with clindamycin, erythromycin or in some cases vancomycin \[[@pone.0226699.ref001]\]. Despite the initial effectiveness of the antibiotic treatment in decreasing GBS EoD in 2002, the rate of overall EoD increased during 2003--2005, reflecting increases in incidence among Black infants \[[@pone.0226699.ref006]\]. The Center for Disease Control reports that as of 2017, GBS remains a leading cause of neonatal sepsis and meningitis, with a national estimate approaching 1000 live births annually (0.22/1000) in the United States developing early-onset meningitis \[[@pone.0226699.ref007]\].

GBS possesses an arsenal of virulence factors, which contribute to host cell attachment, invasion, colonization and progression of invasive disease \[[@pone.0226699.ref008]\]. The sialylated GBS capsular polysaccharide (CPS) represents one of the most critical virulence factors and, thus far, ten capsular serotypes have been identified (Ia, Ib and II--IX). Of the 10 different GBS serotypes described, Ia, Ib, II, III, and V are more commonly associated with disease and account for the majority of cases worldwide \[[@pone.0226699.ref009]\]. GBS has also been classified by sequence type (ST) based on an allelic profile of seven different loci \[[@pone.0226699.ref010]\]. Serotype III strains belonging to the ST-17 background represent a hyper-virulent lineage, which causes a disproportionately high incidence of neonatal invasive disease and meningitis \[[@pone.0226699.ref011]\]. Additional well-studied GBS virulence factors include the β-hemolysin/cytolysin (β-H/C) \[[@pone.0226699.ref012]--[@pone.0226699.ref014]\], serine-rich repeat surface glycoproteins (Srr1/2) \[[@pone.0226699.ref015]--[@pone.0226699.ref019]\], pilus proteins \[[@pone.0226699.ref020]--[@pone.0226699.ref024]\], and surface adhesins known to interact with extracellular matrix components \[[@pone.0226699.ref018], [@pone.0226699.ref025]\]. However, the contribution of these virulence factors to GBS colonization of the vaginal tract is still being elucidated.

In this study, we characterized a panel of 39 GBS clinical isolates collected from the vaginal tracts of pregnant women at the Detroit Medical Center in Detroit, Michigan \[[@pone.0226699.ref019]\]. In order to characterize the disease potential of our strain panel, we assessed capsular serotype by PCR or flow cytometry and the hyper-virulent sequence type (ST-17) in serotype III strains. We also assessed virulence potential by determining vaginal cell adherence, hemolysis, and susceptibility against five of the most clinically relevant antibiotics within the U.S. health care system: penicillin, clindamycin, erythromycin, vancomycin, and tetracycline.

Materials and methods {#sec002}
=====================

Bacterial strains and cell lines {#sec003}
--------------------------------

*Streptococcus agalactiae* (GBS) clinical isolate strains used in this study were A909 \[[@pone.0226699.ref026]\], CJB111(ATCC BAA-23) \[[@pone.0226699.ref027]\], CNCTC10/84 \[[@pone.0226699.ref028]\], COH1 \[[@pone.0226699.ref029]\], H36B \[[@pone.0226699.ref030]\] and the β-H/C-deficient COH1Δ*cylE* \[[@pone.0226699.ref013]\]. GBS strains isolated from the vaginal tracts of pregnant women were purchased from the Detroit Medical Center, Detroit, Michigan; thus, no patient history information is known. Strains were grown on Chrome indicator Agar for GBS (CHROMagar StrepB SB282) as well as confirmed by latex test to confirm the presence of the Group B carbohydrate (Remel Streptex R30950701) \[[@pone.0226699.ref019]\]. Immortalized human vaginal epithelial cells (VK2/E6E7, ATCC CRL-2616) were maintained in keratinocyte serum-free media (Life Technologies) with the addition of 0.1 ng/mL human recombinant epidermal growth factor and 0.05 mg/mL bovine pituitary extract at 37°C in 5% CO~2~ as described previously (18).

Serotyping by PCR and flow cytometric serotyping assay (FCSA) {#sec004}
-------------------------------------------------------------

Molecular serotyping was performed by PCR amplification using Taq DNA polymerase (New England Biolabs, Massachusetts, USA) and primer sequences previously described by Poyart et al. \[[@pone.0226699.ref031]\] ([Table 1](#pone.0226699.t001){ref-type="table"}). Because the serotype III primer set has potential to cross-react with serotype Ia and II *cps* loci due to high sequence identity \[[@pone.0226699.ref031]\], these serotypes were confirmed by flow cytometry using monoclonal antibodies specific for capsular serotypes Ia, II, or III. Since an anti-Ib monoclonal antibody is also available, serotype Ib isolates were further confirmed by flow cytometry, as described previously \[[@pone.0226699.ref032]\], with slight modifications. Monoclonal antibodies specific to GBS serotypes Ia, Ib, II, and III were provided by John Kearney at the University of Alabama at Birmingham \[[@pone.0226699.ref033]--[@pone.0226699.ref036]\]. Serotypes IV and V were determined by PCR alone as monoclonal antibodies specific to serotypes IV and V are not available. Briefly, bacteria were grown to OD~600nm~ = 0.4 and then normalized by to yield \~5x10^5^ CFU/ well in HBC buffer (1× [H]{.ul}BSS without magnesium or calcium, 0.5% [B]{.ul}ovine serum albumin, 2.2 mM [C]{.ul}aCl~2~). Monoclonal antibodies to serotypes Ia, Ib, II, and III were incubated with bacteria at predetermined concentrations of 48 (Ia), 89 (Ib), 6.6 (II), and 77 ng/μL (III) respectively for 30 minutes at 4°C with shaking. Wells were washed two times with HBC and bacteria were incubated with donkey anti-mouse IgM-AF647 (1:2000 final dilution) 30 minutes at 4°C with shaking. Bacteria were washed two times, resuspended in HBC, and analyzed by flow cytometry on a FACSCalibur flow cytometer. Flow cytometric data was analyzed by FlowJo (V10).

10.1371/journal.pone.0226699.t001

###### Primer sequences.

![](pone.0226699.t001){#pone.0226699.t001g}

  Primer Name            Sequence 5' → 3'
  ---------------------- ----------------------------------
  Serotype Ia Forward    `GGTCAGACTGGATTAATGGTATGC`
  Serotype Ia Reverse    `GTAGAAATAGCCTATATACGTTGAATGC`
  Serotype Ib Forward    `TAAACGAGAATGGAATATCACAAACC`
  Serotype Ib Reverse    `GAATTAACTTCAATCCCTAAACAATATCG`
  Serotype II Forward    `GCTTCAGTAAGTATTGTAAGACGATAG`
  Serotype II Reverse    `TTCTCTAGGAAATCAAATAATTCTATAGGG`
  Serotype III Forward   `TCCGTACTACAACAGACTCATCC`
  Serotype III Reverse   `AGTAACCGTCCATACATTCTATAAGC`
  Serotype IV Forward    `GGTGGTAATCCTAAGAGTGAACTGT`
  Serotype IV Reverse    `CCTCCCCAATTTCGTCCATAATGGT`
  Serotype V Forward     `GAGGCCAATCAGTTGCACGTAA`
  Serotype V Reverse     `AACCTTCTCCTTCACACTAATCCT`
  *hvgA* Forward         `ATACAAATTCTGCTGACTACCG`
  *hvgA* Reverse         `TTAAATCCTTCCTGACCATTCC`
  *srr1* Forward         `AGTGTCTGATACTGAAATGTTAGGTA`
  *srr1* Reverse         `TAGATTCCCAAGTCCTGATGCGA`
  *srr2* Forward         `GTTCCGAGTCAGTATCAATGAG`
  *srr2* Reverse         `AATCCTGCACCTAACAGACC`

Determination of hemolytic activity {#sec005}
-----------------------------------

To determine β-hemolytic activity, strains were grown overnight at 37°C and 10 μL was spotted onto sheep blood agar plates (Remel R01200) and incubated overnight at 37°C with 5% CO~2~ \[[@pone.0226699.ref037]\]. The hemolytic activities of vaginal isolates were compared to reference strains COH1Δ*cylE* (-), COH1 (+), A909 (++), and CNCTC10/84 (+++) via blind scoring by two individuals for three biological replicates. Phenotypes from overnight cultures were confirmed using cultures grown to OD~600nm~ 0.4.

Molecular identification of factors contributing to colonization {#sec006}
----------------------------------------------------------------

Isolates were confirmed by PCR for the presence of the genes encoding serine-rich repeat glycoproteins 1 and 2 (*ssr1*, *srr2*) \[[@pone.0226699.ref019]\]. Additionally, all serotype III vaginal isolates were assessed for hyper-virulent sequence type 17 (ST-17) lineage based on detection of the *hvgA* gene (*gbs2018C*) \[[@pone.0226699.ref038]\]. Primer sequences used throughout this study are listed in [Table 1](#pone.0226699.t001){ref-type="table"}.

Bacterial adherence assay {#sec007}
-------------------------

GBS adherence to VK2/E6E7 was determined as described previously \[[@pone.0226699.ref017], [@pone.0226699.ref019], [@pone.0226699.ref039], [@pone.0226699.ref040]\]. Briefly, vaginal epithelial cells were seeded into tissue culture treated 96-well plates and grown to 90--100% confluence. Clinical isolates were grown to OD~600nm~ 0.4 in Todd-Hewitt broth and inoculated onto vaginal cell monolayers at 1x10^4^ CFU, MOI = 1. Plates were centrifuged at 1000 RPM (169 x g) for 5 minutes and incubated at 37°C with 5% CO~2~ for 30 minutes. Following incubation, plates were rinsed five times with PBS to remove non-adherent bacteria. Vaginal cells were then detached with 0.25% trypsin-EDTA and lysed with 0.025% Triton-X-100 in phosphate-buffered saline. Lysates were diluted and plated to quantitate adherent CFU. Assays were performed in triplicate wells in biological triplicate experiments.

Antibiotic sensitivity profiling {#sec008}
--------------------------------

Overnight cultures of GBS strains were spread on Todd Hewitt agar. Discs impregnated with antibiotics at the following concentrations were added and plates were incubated overnight at 37°C (Penicillin 10 U, Clindamycin 2 mg, Erythromycin 15 mg, Vancomycin 30 μg, and Tetracycline 30 μg) \[[@pone.0226699.ref041]\]. Following overnight incubation, zones of inhibition surrounding antibiotic discs were measured. Disc diffusion was performed two times for each strain and antibiotic tested. Zones of inhibition were characterized as susceptible, intermediate, or resistant based on the following measurement determinations: Penicillin (Resistant ≤23 mm, Susceptible ≥24 mm), Clindamycin (Resistant ≤15 mm, Intermediate 16--18 mm, Susceptible ≥19 mm), Erythromycin (Resistant ≤15 mm, Intermediate 16--20 mm, Susceptible ≥21 mm), Vancomycin (Resistant ≤16 mm Susceptible ≥17 mm), and Tetracycline (Resistant ≤18 mm, Intermediate 19--22, and Susceptible ≥23 mm). As penicillin and vancomycin do not have an intermediate range, zones measuring larger than the susceptible limit were deemed resistant.

Statistical analyses {#sec009}
--------------------

Adherence assays performed in this study were conducted three times independently with triplicate samples. Data are displayed as averages from the three independent experiments and analyzed by one-way ANOVA with Sidak's multiple comparisons. All analyses were conducted with α = 0.05 and statistical significance determined as *p* \< α. All statistical analyses were performed using GraphPad Prism 7 and R Studio.

Results {#sec010}
=======

Serotype distribution and virulence potential of vaginal clinical isolates {#sec011}
--------------------------------------------------------------------------

Molecular serotype was determined by PCR using primers specific to various serotypes' *cps* loci as described in Poyart et al. \[[@pone.0226699.ref031]\] ([Table 2](#pone.0226699.t002){ref-type="table"}). Serotypes Ia, Ib, II, and III were confirmed by flow cytometry, utilizing monoclonal antibodies against GBS capsule ([S1 Fig](#pone.0226699.s001){ref-type="supplementary-material"}). Serotypes V and III constituted over half of the colonizing isolates at 28.2% (11/39) and 25.6% (10/39), respectively ([Table 2](#pone.0226699.t002){ref-type="table"}). The remaining isolates were identified as serotype II (15.4%, 6/39), Ia (12.8%, 5/39), Ib (15.4%, 6/39), and IV (2.6%, 1/39) ([Table 2](#pone.0226699.t002){ref-type="table"}). In addition to capsular serotype, GBS strain background is also known to contribute to virulence potential. In particular, strains belonging to sequence type 17 (ST-17) are hyper-virulent and commonly associated with invasive disease, specifically meningitis \[[@pone.0226699.ref010], [@pone.0226699.ref038]\]. Additional bacterial factors known to contribute to virulence in GBS are the serine-rich repeat glycoproteins Srr1 or Srr2 \[[@pone.0226699.ref018], [@pone.0226699.ref019], [@pone.0226699.ref042], [@pone.0226699.ref043]\]. We therefore assessed the presence of the *hvgA* gene (*gbs2018C*) (indicative of ST-17) and *srr1*/*srr2* genes within our strain panel by PCR. We confirmed that 50% of our serotype III strains belonged to the ST-17 lineage and encoded *srr2* ([Table 2](#pone.0226699.t002){ref-type="table"}). The sole serotype IV strain within our panel also encoded *srr2* whereas the remaining 31/33 (94%) GBS vaginal isolates encoded *srr1*.

10.1371/journal.pone.0226699.t002

###### Clinical isolate serotype distribution.

![](pone.0226699.t002){#pone.0226699.t002g}

  ----------------------------------------------------------------------------------------------
  Serotype             Ia           Ib           II           III          IV       V
  -------------------- ------------ ------------ ------------ ------------ -------- ------------
  **Strain numbers**   5^**◊**^\    3^**◊**^\    6^**◊**^\    4\*^\#^\     51^\#^   1^**◊**^\
                       17^**◊**^\   10^**◊**^\   16^**◊**^\   9\*^\#^\              2^**◊**^\
                       48^**◊**^\   14^**◊**^\   31^**◊**^\   24\*^\#^\             12^**◊**^\
                       67^**◊**^\   30^**◊**^\   54^**◊**^\   29\                   15^**◊**^\
                       68^**◊**^    62^**◊**^\   56^**◊**^\   40\*^\#^\             20^**◊**^\
                                    63^**◊**^    64^**◊**^    43^**◊**^\            27^**◊**^\
                                                              52\                   28^**◊**^\
                                                              59^**◊**^\            33^**◊**^\
                                                              69\*^\#^\             39^**◊**^\
                                                              71^**◊**^             41^**◊**^\
                                                                                    57^**◊**^

  ----------------------------------------------------------------------------------------------

The displayed symbols correlate with isolates of sequence type-17 (ST-17) (\*) or isolates expressing *srr1* (◊) or *srr2* (\#).

Hemolytic activity {#sec012}
------------------

GBS hemolytic activity is associated with increased virulence \[[@pone.0226699.ref012]--[@pone.0226699.ref014]\]; thus, we assessed hemolytic activity of the vaginal clinical isolates as described in the Methods. We compared the observed hemolytic activity of GBS vaginal isolates to reference GBS strains COH1Δ*cylE* (-), COH1 (+), A909 (++), and CNCTC10/84 (+++). The majority of vaginal isolates exhibited hemolysis at levels similar to invasive isolates COH1 (19/39, 48.7%) and A909 (16/39, 41%) ([Table 3](#pone.0226699.t003){ref-type="table"}, [S2 Fig](#pone.0226699.s002){ref-type="supplementary-material"}). However, we also identified two non-hemolytic isolates (similar to the COH1Δ*cylE* strain) and two hyper-hemolytic isolates (similar to the CNCTC10/84 strain). Collectively, a wide range of hemolytic activity was observed across our isolate panel, with most strains displaying detectable but low hemolytic activity. ([Table 3](#pone.0226699.t003){ref-type="table"}, [S2 Fig](#pone.0226699.s002){ref-type="supplementary-material"})

10.1371/journal.pone.0226699.t003

###### Clinical isolate hemolytic activity.

![](pone.0226699.t003){#pone.0226699.t003g}

  Clinical Isolate Hemolytic Activity                                                                                                                                                   
  ------------------------------------- -------- ------------------------------------------------------------------------- ------------------------------------------------------------ --------
  Vaginal Isolates                      29, 52   1, 2, 4, 12, 16, 17, 24, 28, 31, 33, 39, 40, 41, 51, 54, 56, 57, 64, 69   3, 5, 6, 9, 14, 15, 20, 27, 30, 43, 59, 62, 63, 67, 68, 71   10, 48

Adherence of clinical isolates to vaginal epithelial cells {#sec013}
----------------------------------------------------------

We have shown previously that GBS disease isolates are capable of adhering to human vaginal epithelial cells \[[@pone.0226699.ref017], [@pone.0226699.ref019], [@pone.0226699.ref039], [@pone.0226699.ref040]\]. To determine the ability of these colonizing isolates to adhere to vaginal epithelium, all strains were incubated with the human vaginal epithelial cell line VK2/E6E7 and adherent bacteria were recovered as described in the Methods. GBS vaginal isolates revealed a wide range of adherence (5--45% of the original inoculum, [Fig 1A](#pone.0226699.g001){ref-type="fig"}), levels similar to those of disease isolates of the same serotype: A909 (Ia), COH1 (III), and CJB111 (V) (denoted by the diamond symbols, [Fig 1B](#pone.0226699.g001){ref-type="fig"}).

![Vaginal epithelial cell adherence.\
A) Adherence of GBS clinical isolates to human vaginal epithelial cells (VK2/E6E7) at MOI = 1. Data represent the average of three independent experiments, each performed with three technical replicates. B) Adherence separated by serotype along the x-axis and compared to invasive isolates COH1, A909, and CJB111, denoted by diamonds. Open symbols represent isolates belonging to the hyper-virulent sequence type 17 (ST-17) lineage. Data were analyzed by a one-way ANOVA with Sidak's multiple comparisons test, with each serotype compared to all others. Non-ST-17 samples (Ia, Ib, II, III, IV, and V) were compared to serotype III, ST-17 strains, \*\*\*\* *p* \< 0.0001. No significant differences were detected between non-ST-17 samples. C) Adherence percentages separated by the presence of serine-rich repeat glycoproteins (Srr1 or Srr2). Symbol colors in panels B & C indicate capsular serotype. Data were analyzed by a one-way ANOVA with Sidak's multiple comparisons test, \*\*\*\* *p* \< 0.0001.](pone.0226699.g001){#pone.0226699.g001}

Because ST-17 strains are commonly associated with invasive disease we assessed whether isolates of this strain background would exhibit increased attachment to VK2/E6E7 monolayers. Indeed, ST-17, serotype III strains adhered significantly better to vaginal epithelium compared to non-ST-17 serotype III strains (32.2% and 12.5%, respectively, *p* \< 0.0001), suggesting that the ST-17 background confers an adherence advantage in serotype III strains ([Fig 1B](#pone.0226699.g001){ref-type="fig"}). Serotype III, ST-17 strains were significantly more adherent than serotypes Ia, Ib, II, and V (*p* \< 0.0001), but exhibited similar adherence as the serotype IV strain as this strain also expressed Srr2 ([Fig 1B](#pone.0226699.g001){ref-type="fig"}). Additionally, no significant differences in adherence were detected across serotypes Ia, Ib, II, III non-ST-17, IV, and V ([Fig 1B](#pone.0226699.g001){ref-type="fig"}). As expected, we observed that Srr2*-*positive strains (which are typically of ST-17 lineage \[[@pone.0226699.ref044], [@pone.0226699.ref045]\]) exhibited increased adherence compared to Srr1*-*positive isolates (*p* \< 0.0001) ([Fig 1C](#pone.0226699.g001){ref-type="fig"}).

Antibiotic sensitivity profiling of clinical isolate panel {#sec014}
----------------------------------------------------------

Rising antibiotic resistance has been reported in the literature in pathogens and commensal microbiota. As antibiotic prophylaxis during delivery is the primary measure taken to prevent GBS ascending infection and transmission to the neonate, it is imperative to monitor effective antibiotic treatment regimens. Currently, penicillin is the first-line antibiotic for pregnant women testing positive for GBS by rectovaginal swabs. In the case of penicillin allergy, women are prescribed clindamycin, erythromycin, or, vancomycin \[[@pone.0226699.ref001]\]. To determine the efficacy of these clinically relevant antibiotics against this panel of colonizing isolates, we used an antibiotic disc diffusion assay. Of the 39 isolates in this panel, 15.4% (6/39) were resistant to the first-line antibiotic, penicillin, 30.8% (12/39) were resistant to clindamycin, and 30.8% (12/39) were resistant to vancomycin ([Table 4](#pone.0226699.t004){ref-type="table"}, [Fig 2](#pone.0226699.g002){ref-type="fig"}). Further, 59% (23/39) of isolates exhibited either resistance (17/39) or intermediate susceptibility (6/39) to erythromycin. Lastly, 94.9% (37/39) of strains were identified as tetracycline resistant with only 5% (2/39) displaying an intermediate resistance phenotype. Collectively all 39 strains were not susceptible to tetracycline; however, this is unsurprising as high tetracycline resistance in GBS has been observed historically \[[@pone.0226699.ref046]\]. To determine if capsular serotype is associated with GBS susceptibility to antibiotics, vaginal isolates were grouped by serotype ([Table 4](#pone.0226699.t004){ref-type="table"}) and analyzed using Fisher's exact test. We observed that resistance to penicillin and clindamycin were significantly associated with serotype (*p* = 0.03 and *p* = 0.04, respectively), with the majority of penicillin- and clindamycin-resistant strains belonging to serotypes II and V.

![Antibiotic sensitivity of isolate panel.\
Antibiotic suscpetibility profiles (determined by disc diffusion measurement) displayed in a heat map with blue boxes indicating susceptible isolates, gray boxes indicating intermediate isolates, and red boxes indicating resistant isolates. Antibiotic discs were used at the following concentrations: penicillin 10 U, clindamycin 2 mg, erythromycin 15 mg, vancomycin 30 μg, and tetracycline 30 μg.](pone.0226699.g002){#pone.0226699.g002}

10.1371/journal.pone.0226699.t004

###### Antibiotic sensitivity distribution by serotype.

![](pone.0226699.t004){#pone.0226699.t004g}

  -------------------------------------------------------------------------
                      Antibiotic   Susceptible   Intermediate   Resistant
  ------------------- ------------ ------------- -------------- -----------
  **Composite**\      Penicillin   33 (84.6%)    NA             6 (15.4%)
  **N = 39**                                                    

  Clindamycin         27 (69.2%)   0             12 (30.8%)     

  Erythromycin        16 (41.0%)   6 (15.4%)     17 (43.6%)     

  Vancomycin          27 (69.2%)   NA            12 (30.8%)     

  Tetracycline        0            2 (5.1%)      37 (94.9%)     

  **Serotype Ia**\    Penicillin   5 (100%)      NA             0
  **N = 5**                                                     

  Clindamycin         5 (100%)     0             0              

  Erythromycin        2 (40%)      0             3 (60%)        

  Vancomycin          4 (80%)      NA            1 (20%)        

  Tetracycline        0            0             5 (100%)       

  **Serotype Ib**\    Penicillin   6 (100%)      NA             0
  **N = 6**                                                     

  Clindamycin         5 (83%)      0             1 (17%)        

  Erythromycin        3 (50%)      0             3 (50%)        

  Vancomycin          5 (83%)      NA            1 (17%)        

  Tetracycline        0            0             6 (100%)       

  **Serotype II**\    Penicillin   4 (67%)       NA             2 (33%)
  **N = 6**                                                     

  Clindamycin         1 (17%)      0             5 (83%)        

  Erythromycin        2 (33%)      0             4 (67%)        

  Vancomycin          3 (50%)      NA            3 (50%)        

  Tetracycline        0            1 (17%)       5 (83%)        

  **Serotype III**\   Penicillin   10 (100%)     NA             0
  **N = 10**                                                    

  Clindamycin         8 (80%)      0             2 (20%)        

  Erythromycin        4 (40%)      3 (30%)       3 (30%)        

  Vancomycin          9 (90%)      NA            1 (10%)        

  Tetracycline        0            1 (10%)       9 (90%)        

  **Serotype IV**\    Penicillin   0             NA             1 (100%)
  **N = 1**                                                     

  Clindamycin         1 (100%)     0             0              

  Erythromycin        1 (100%)     0             0              

  Vancomycin          0            NA            1 (100%)       

  Tetracycline        0            0             1 (100%)       

  **Serotype V**\     Penicillin   8 (73%)       NA             3 (27%)
  **N = 11**                                                    

  Clindamycin         7 (64%)      0             4 (36%)        

  Erythromycin        4 (36%)      3 (27%)       4 (36%)        

  Vancomycin          6 (55%)      NA            5 (45%)        

  Tetracycline        0            0             11 (100%)      
  -------------------------------------------------------------------------

Discussion {#sec015}
==========

Herein we have characterized 39 GBS isolates obtained from the vaginal tracts of pregnant women. We have evaluated the serotype and antibiotic susceptibility of these isolates to front-line drugs and have functionally assessed isolates for parameters important for vaginal colonization, including adherence to human vaginal epithelial cells and hemolytic activity. We found that the most abundant serotypes in this collection were serotype V and III, with the order of most abundant to least abundant serotype being V \> III \> II \> Ia/Ib \> IV. The serotype distribution of our panel supports previous literature as either serotype V or III have been reported as the most prevalent serotype in 18 of 23 studies conducted on GBS colonizing isolates since 2007 ([Table 5](#pone.0226699.t005){ref-type="table"}). Serotypes Ia, Ib, and II have also been reported among the top three most prevalent serotypes in these studies ([Table 5](#pone.0226699.t005){ref-type="table"}). Serotype IV appears to be relatively rare as it was seldom seen in vaginal isolates across all studies, including the isolate cohort presented here. Although some studies of clinical isolates from Africa or Asia reported increased prevalence of more recently discovered serotypes VI, VII, and VIII, we did not identify any of these serotypes in our cohort.

10.1371/journal.pone.0226699.t005

###### Serotype and antibiotic resistance profiles across relevant literature.

![](pone.0226699.t005){#pone.0226699.t005g}

                                                           Percentages of Antibiotic Resistance, n (%)                                                                                
  -------------------------------------------------------- --------------------------------------------- --------------------- ----------- ------------ -------------- -------------- --------------
  *Present Study*                                          Michigan, USA                                 V, 11/39 (28.2)       6/39 (15)   12/39 (31)   17/39 (44)     12/39 (31)     37/39 (95)
  *A'Hearn-Thomas \[[@pone.0226699.ref047]\]*              Botswana                                      V, 24/53 (45.3)       \_\_\_      \_\_\_       \_\_\_         \_\_\_         \_\_\_
  *Belard et al*. *2015* \[[@pone.0226699.ref048]\]        Gabon, Africa                                 V, 33/109 (30.3)      0/109 (0)   \_\_\_       0/109 (0)      0/109 (0)      \_\_\_
  *Botelho et al*. *2018* \[[@pone.0226699.ref049]\]       Brazil                                        Ia, 257/689 (37.3)    \_\_\_      0/689 (0)    97/689 (14)    14/689 (2)     592/689 (86)
  *Chukwu et al*. *2015* \[[@pone.0226699.ref050]\]        South Africa                                  III, 38/128 (29.7)    \_\_\_      \_\_\_       \_\_\_         \_\_\_         \_\_\_
  *Correa et al*. *2011* \[[@pone.0226699.ref051]\]        Brazil                                        Ia, 20/60 (33.2)      0/60 (0)    0/60 (0)     8/60 (13)      10/60 (17)%    49/60 (82)
  *Dutra et al*. *2018* \[[@pone.0226699.ref052]\]         Brazil                                        Ia, 120/434 (27.6)    \_\_\_      \_\_\_       18/434 (4)     13/434 (3)     420/434 (97)
  *El Aila et al*. *2009* \[[@pone.0226699.ref053]\]       Belgium                                       III (20.8)            \_\_\_      \_\_\_       11/40 (28)     3/40 (8)       \_\_\_
  *Eskandarian et al*. *2015* \[[@pone.0226699.ref054]\]   Malaysia                                      VI, 23/103 (22.3)     0/103 (0)   \_\_\_       24/103 (23)    18/103 (18)    74/103 (72)
  *Florindo et al*. *2010* \[[@pone.0226699.ref055]\]      Portugal                                      III, 35/100 (35)      0/100 (0)   0/100 (0)    19/100 (19)    \_\_\_\_\_\_   \_\_\_
  *Hannoun et al*. *2009* \[[@pone.0226699.ref056]\]       Lebanon                                       III, 15/76 (19.7)     0/76 (0)    \_\_\_       12/76 (16)     9/76 (12)      66/76 (87)
  *Ji et al. 2017 \[[@pone.0226699.ref057]\]*              China                                         III, 84/153 (54.9)    0/153 (0)   0/153 (0)    99/153 (65)    80/153 (52)    \_\_\_
  *Khatami 2019 \[[@pone.0226699.ref058]\]*                New York, USA                                 III, 12/25 (48)       \_\_\_      \_\_\_       \_\_\_         \_\_\_         \_\_\_
  *Khodaei et al*. *2018* \[[@pone.0226699.ref059]\]       Iran                                          III, 62/90 (68.9)     0/90 (0)    1/90 (1)     27/90 (30)     89/90 (99)     89/90 (99)
  *Liakopolous et al*. 2014 \[[@pone.0226699.ref060]\]     Greece                                        III, 17/26 (65.4)     0/26 (0)    0/26 (0)     22/26 (84.6)   21/26 (82)     26/26 (100)
  *Mavenyengwa et al*. 2010 \[[@pone.0226699.ref061]\]     Zimbabwe                                      III, 47/121 (38.8)    \_\_\_      \_\_\_       \_\_\_         \_\_\_         \_\_\_
  *Pinto et al*. *2018* \[[@pone.0226699.ref062]\]         Portugal                                      III, 15/67 (22.4)     \_\_\_      \_\_\_       \_\_\_         \_\_\_         \_\_\_
  *Sadeh et al*. *2016* \[[@pone.0226699.ref063]\]         Iran                                          III, 50/100 (50)      \_\_\_      \_\_\_       \_\_\_         \_\_\_         \_\_\_
  *Seo et al. 2010 \[[@pone.0226699.ref064]\]*             Korea                                         III, 112/376 (29.8)   \_\_\_      \_\_\_       \_\_\_         \_\_\_         \_\_\_
  *Slotved et al*. *2017* \[[@pone.0226699.ref065]\]       Ghana                                         VII, 44/108 (40.7)    \_\_\_      \_\_\_       \_\_\_         \_\_\_         \_\_\_
  *Smith et al*. *2007* \[[@pone.0226699.ref066]\]         Michigan & Texas, USA                         Ia, 101/421 (24)      \_\_\_      \_\_\_       \_\_\_         \_\_\_         \_\_\_
  *Teatero et al. 2017 \[[@pone.0226699.ref067]\]*         USA & Canada                                  III, 26/102 (25.5)    0/102 (0)   0/102 (0)    37/102 (36)    25/102 (25)    91/102 (89)
  *Ueno et al*. *2012* \[[@pone.0226699.ref068]\]          Japan                                         V, 72/376 (19.1)      0/376 (0)   0/376 (0)    48/376 (13)    34/376 (9)     175/376 (47)
  *Usein et al*. *2014* \[[@pone.0226699.ref069]\]         Bucharest                                     V, 20/55 (36.4)       0/43 (0)    \_\_\_       19/43 (44)     19/43 (44)     43/43 (100)

In addition to serotyping, we functionally assessed our panel of isolates for hemolytic activity and the ability to adhere to human vaginal epithelial cells. When plated on blood agar, low levels of hemolysis (similar to that of COH1 and A909 strains) were detected in 35/39 vaginal isolates. Although there were some isolates that exhibited either non-detectable levels of hemolysis (similar to the COH1Δ*cylE* strain) (2/39) or high levels of hemolysis (similar to the hyper-hemolytic strain CNCTC10/84) (2/39) ([Table 3](#pone.0226699.t003){ref-type="table"}). Previous studies have shown that GBS strains producing the β-H/C have an advantage in vaginal colonization as well as placental invasion compared to strains deficient in β-H/C \[[@pone.0226699.ref070], [@pone.0226699.ref071]\]. Since the majority of the vaginal isolates in our panel exhibit low levels of hemolytic activity, our data suggest that strains producing high levels of β-H/C may be selected against during colonization of the vagina. This is supported by our previous observations that hyper-hemolytic strain CNCTC10/84 resulted in increased pro-inflammatory cytokine production in vaginal epithelial cells and more rapid clearance from the murine vaginal tract \[[@pone.0226699.ref072]\]. The global regulator CovR regulates β-H/C, specifically repressing its expression in acidic environments, such as that of the vaginal mucosa \[[@pone.0226699.ref073], [@pone.0226699.ref074]\]. We therefore hypothesize that during vaginal carriage, CovR may suppress β-H/C expression resulting in decreased inflammation and more persistent GBS colonization. Alternatively, in neutral environments such as the chorioamniotic membrane, β-H/C may be expressed, potentiating invasion by hyper-hemolytic GBS strains \[[@pone.0226699.ref037]\].

Adherence to epithelial barriers promotes successful GBS colonization the vaginal tract. All strains in this cohort were able to adhere to vaginal epithelial cells, though adherence capabilities varied greatly across strains ([Fig 1A](#pone.0226699.g001){ref-type="fig"}). We observed that 5--45% of the original bacterial inoculum attached to VK2/E6E7 monolayers. Serotype III isolates exhibited the highest level of adherence compared to the isolates of the remaining serotypes tested. Of the serotype III isolates, ST-17 and Srr2 were associated with increased adherence compared to non-ST-17 strains, which typically express Srr1 ([Fig 1B & 1C](#pone.0226699.g001){ref-type="fig"}). Strains belonging to the hyper-virulent ST-17 background exclusively express serotype III capsule \[[@pone.0226699.ref075], [@pone.0226699.ref076]\] and are significantly associated with LoD and meningitis \[[@pone.0226699.ref075], [@pone.0226699.ref077], [@pone.0226699.ref078]\]. The propensity of ST-17/serotype III strains to cause invasive meningeal disease has been attributed to expression of ST-17 associated factors, such as hyper-virulent GBS adhesin (HvgA) and serine-rich repeat (Srr) glycoprotein Srr2 \[[@pone.0226699.ref011], [@pone.0226699.ref015], [@pone.0226699.ref038], [@pone.0226699.ref043], [@pone.0226699.ref076]\]. HvgA, a cell-wall anchored surface protein, has been implicated in colonization and invasion of both the intestine and the blood brain barrier, and detection of the *hvgA* gene (*gbs2018C*) is the basis for the ST-17 PCR used in this study and others \[[@pone.0226699.ref038]\]. The contribution of HvgA to GBS colonization of the female reproductive tract has not been demonstrated, but HvgA expression may contribute to the increased adherence by ST17/serotype III isolates to vaginal epithelium compared to other isolates observed in this study ([Fig 1B](#pone.0226699.g001){ref-type="fig"}). In addition to HvgA, ST-17 strains exclusively express Srr2 (instead of Srr1), which has been shown to promote virulence *in vivo* \[[@pone.0226699.ref015]\] and adherence to vaginal epithelium, *in vitro* \[[@pone.0226699.ref017]\]. Indeed, in the present study strains harboring the *srr2* gene exhibited increased adherence to vaginal epithelium compared to other isolates ([Fig 1C](#pone.0226699.g001){ref-type="fig"}). Previous studies have also shown that both Srr1 and Srr2 interact with host fibrinogen \[[@pone.0226699.ref018], [@pone.0226699.ref019], [@pone.0226699.ref043]\]; however, Srr2 specifically is more abundant on the bacterial cell surface and binds fibrinogen with an increased affinity compared to Srr1 \[[@pone.0226699.ref042], [@pone.0226699.ref043]\]. We therefore hypothesize that the increased epithelial adherence potential of these Srr2-expressing strains may promote increased transmission to the neonate and subsequently contribute to the development of neonatal infections \[[@pone.0226699.ref010], [@pone.0226699.ref079]\]. Previous literature indicates that bacterial hemolytic activity may also contribute to GBS adherence to host cells; yet, this association remains controversial \[[@pone.0226699.ref040], [@pone.0226699.ref080]\]. Our data suggest that hemolytic activity did not impact the ability of GBS to adhere to vaginal epithelium ([S3 Fig](#pone.0226699.s003){ref-type="supplementary-material"}). This has similarly been reported by *Whidbey et al*. \[[@pone.0226699.ref037]\].

Upon assessment of antibiotic susceptibility, we found that this set of clinical isolates exhibited various levels of antibiotic resistance. Specifically, we observed that 30.8% of isolates were resistant to clindamycin, 43.6% to erythromycin, and 94.9% to tetracycline ([Fig 2](#pone.0226699.g002){ref-type="fig"}, [Table 4](#pone.0226699.t004){ref-type="table"}). High percentages of tetracycline resistance have been detected in GBS clinical isolates and reported since 1975 \[[@pone.0226699.ref046]\]. Of specific interest within our data set was an increased resistance to penicillin in roughly 15% of strains in our panel. This was particularly striking when penicillin resistance was broken down by serotype. Serotype II and V strain groups harbored all penicillin resistant isolates, exhibiting 33% and 27% penicillin resistance, respectively. Though the first GBS isolates displaying reduced penicillin susceptibility were detected in sputum samples in 2008 \[[@pone.0226699.ref081]\], penicillin resistance was not reported in GBS vaginal isolates until 2014 by Crespo-Ortiz et al. \[[@pone.0226699.ref082]\]. More recently, reports have detected reduced sensitivity to β-lactam antibiotics in GBS isolates collected from pregnant women \[[@pone.0226699.ref083], [@pone.0226699.ref084]\]. Our study and others indicate that not only is penicillin-resistance among vaginal isolates rising, but it may be localized to particular serotypes \[[@pone.0226699.ref083], [@pone.0226699.ref084]\]. Because of this, future GBS serotyping may be integral to effectively treating GBS-positive pregnant women before delivery. Additionally, many isolates in this collection were found to be vancomycin-resistant ([Table 4](#pone.0226699.t004){ref-type="table"}), which has not been commonly reported in previous studies of vaginal GBS isolates. Although vancomycin-resistant isolates were found in every serotype present in our cohort, vancomycin resistance was enriched in serotypes II and V (50% and 45% resistant, respectively). Additionally, three isolates in our panel were resistant to all antibiotics tested. This poses a significant public health risk as antibiotics are the only current therapeutic for GBS infection.

In conclusion, here we have characterized a GBS clinical isolate cohort collected from the vaginal tracts of pregnant women by means of molecular and capsular serotyping, antibiotic susceptibility profiling, and assessing the virulence potential. The serotype prevalence and resistance of erythromycin, tetracycline and clindamycin within our cohort match other epidemiological studies in the literature for colonizing GBS isolates. We describe an emergence of vancomycin-resistant and penicillin-resistant strains, especially within serotypes II and V and describe three isolates that are resistant to all of the front-line antibiotics for GBS. Finally, our study confirms the importance of GBS surface protein Srr2 and ST-17 in successful GBS adherence to the vaginal epithelium. This collection of isolates will be a useful tool in testing strain heterogeneity in models of GBS colonization.

Supporting information {#sec016}
======================

###### Serotyping of vaginal clinical isolates by flow cytometry using anti-capsule monoclonal antibodies.

Histograms display binding by various anti-capsular monoclonal antibodies (identified by color: serotype Ia, green; serotype Ib, orange; serotype II, red; serotype III, blue). The y-axis indicates number of events normalized to the mode and the x-axis indicates fluorescent intensity. Isotype control monoclonal antibodies against non-cognate capsule were utilized as negative controls and are indicated by the light gray histograms. All serotype Ia, Ib, II, and III isolates designated by molecular means (PCR) were tested by FCSA from two independent cultures in two independent experiments.

(TIF)

###### 

Click here for additional data file.

###### Hemolytic activity of colonizing clinical isolate panel.

Hemolytic zone of clearance is shown for vaginal clinical isolates and for reference strains COH1Δ*cylE* (-), COH1 (+), A909 (++), and CNCTC10/84 (+++) after inoculation onto sheep blood agar plates.

(TIF)

###### 

Click here for additional data file.

###### Correlation of hemolytic activity with vaginal epithelial cell adherence.

Adherence of GBS clinical isolates to human vaginal epithelial cells (VK2/E6E7) is shown separated by hemolytic activity (score of -, +, ++, +++ as determined in [Table 3](#pone.0226699.t003){ref-type="table"}) along the x-axis. Symbol colors indicate capsular serotype assigned in [Table 2](#pone.0226699.t002){ref-type="table"}. Data were analyzed by a one-way ANOVA with Sidak\'s multiple comparisons test, NS = not significant.

(TIF)

###### 

Click here for additional data file.
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